Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656748 | 0.89 | MAPK1 (0.51) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL19723527 | 0.87 | LMNA (0.50) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL19723525 | 0.86 | MAPK1 (0.54) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL19723524 | 0.86 | MAPK1 (0.53) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL19723661 | 0.86 | MAPT (0.47) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL1768201 | 0.85 | RAB9A (0.69) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL19723663 | 0.84 | SMN1; SMN2 (0.46) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL21893931 | 0.83 | MAPT (0.45) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL4538242 | 0.83 | KMT2A (0.57) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL16447607 | 0.83 | MAPK1 (0.65) | MAPK1KMT2ASMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| EP-1838711-A2 | ANTI-TUMOR COMPOUNDS | National Health Research Institutes (TW) | 2007-10-03 | — | — | EP | disclosed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006074041-A2 | ANTI-TUMOR COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148801-A1 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-06 | — | — | US | disclosed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148801-A1 | Anti-tumor compounds | TUBB1, TUBB3, TUBB | MAPK1 3266/4885KMT2A 2151/4885SMN1; SMN2 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.